BG103631A - 2-aminosubstituted pyridines applied for the treatment of atherosclerosis and hyperlipoproteinaemia - Google Patents

2-aminosubstituted pyridines applied for the treatment of atherosclerosis and hyperlipoproteinaemia

Info

Publication number
BG103631A
BG103631A BG103631A BG10363199A BG103631A BG 103631 A BG103631 A BG 103631A BG 103631 A BG103631 A BG 103631A BG 10363199 A BG10363199 A BG 10363199A BG 103631 A BG103631 A BG 103631A
Authority
BG
Bulgaria
Prior art keywords
aminosubstituted
pyridines
atherosclerosis
treatment
hyperlipoproteinaemia
Prior art date
Application number
BG103631A
Other languages
Bulgarian (bg)
English (en)
Inventor
Carsten Schmeck
Arndt Brandes
Michael Loegers
Guenter Schmidt
Klaus-Dieter Bremm
Hilmar Bischoff
Delf Schmidt
Joachim Schuhmacher
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of BG103631A publication Critical patent/BG103631A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
BG103631A 1997-02-05 1999-08-03 2-aminosubstituted pyridines applied for the treatment of atherosclerosis and hyperlipoproteinaemia BG103631A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19704243A DE19704243A1 (de) 1997-02-05 1997-02-05 Neue 2-Amino-substituierte Pyridine
PCT/EP1998/000362 WO1998034920A1 (de) 1997-02-05 1998-01-23 2-amino-substituierte pyridine verwendbar zur behandlung von arteriosklerose und hyperlipoproteinemie

Publications (1)

Publication Number Publication Date
BG103631A true BG103631A (en) 2000-11-30

Family

ID=7819326

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103631A BG103631A (en) 1997-02-05 1999-08-03 2-aminosubstituted pyridines applied for the treatment of atherosclerosis and hyperlipoproteinaemia

Country Status (19)

Country Link
EP (1) EP0973744A1 (id)
JP (1) JP2001510478A (id)
KR (1) KR20000070756A (id)
CN (1) CN1252057A (id)
AU (1) AU730109B2 (id)
BG (1) BG103631A (id)
BR (1) BR9807181A (id)
CA (1) CA2279636A1 (id)
CZ (1) CZ279299A3 (id)
DE (1) DE19704243A1 (id)
HU (1) HUP0001022A2 (id)
ID (1) ID24208A (id)
IL (1) IL131127A0 (id)
NO (1) NO993738L (id)
NZ (1) NZ337011A (id)
PL (1) PL334899A1 (id)
SK (1) SK104099A3 (id)
TR (1) TR199901857T2 (id)
WO (1) WO1998034920A1 (id)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
JP4547148B2 (ja) 2001-06-22 2010-09-22 ベンド・リサーチ・インコーポレーテッド 非晶質薬剤の吸着物の医薬組成物
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
RU2330682C2 (ru) 2003-09-26 2008-08-10 Джапан Тобакко Инк. Способ ингибирования продуцирования остаточных липопротеинов
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006032987A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Indoline compounds and their use in the treatment of arteriosclerosis
EP2548894A1 (en) 2005-02-03 2013-01-23 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
US20100113473A1 (en) 2008-10-30 2010-05-06 Player Mark R Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis

Also Published As

Publication number Publication date
TR199901857T2 (xx) 1999-10-21
JP2001510478A (ja) 2001-07-31
KR20000070756A (ko) 2000-11-25
NO993738L (no) 1999-09-17
NO993738D0 (no) 1999-08-02
ID24208A (id) 2000-07-13
AU730109B2 (en) 2001-02-22
NZ337011A (en) 2001-04-27
AU6212398A (en) 1998-08-26
CN1252057A (zh) 2000-05-03
EP0973744A1 (de) 2000-01-26
WO1998034920A1 (de) 1998-08-13
CA2279636A1 (en) 1998-08-13
DE19704243A1 (de) 1998-08-06
PL334899A1 (en) 2000-03-27
HUP0001022A2 (hu) 2000-09-28
SK104099A3 (en) 2000-01-18
BR9807181A (pt) 2000-01-25
CZ279299A3 (cs) 1999-11-17
IL131127A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
ATE233738T1 (de) Kleine moleküle anwendbar in der behandlung von entzündgskrankheiten
TR199700213A2 (xx) 2-Aril s�bstit�entli piridinler.
IL130260A0 (en) 3-thiocarbamoylpyrazole derivatives as pesticides
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
BG104056A (en) Triazole compounds and their use as dopamine-d3-ligands
ATE197897T1 (de) Hautpflegemittel
MY118207A (en) Cycloalkano-pyridines
MY129973A (en) Sulphonylbenzyl-substituted pyridones.
BG101131A (en) 2-oxo-and 2-thio-1,2-dihydroquinolinyl-oxazolidinons
BG103556A (en) 3-pyridyl enantiomers and their application as analgetics
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
WO1999041237A8 (en) Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
MX9700885A (es) Nuevas heteroariloxazolidinonas.
EP0625507A3 (en) Urea derivatives and their use as acat inhibitors
IL113450A (en) Process for the preparation of high solubility multicomponent inclusion complexes consisting of an acidic drug a cyclodextrin and a base and the complexes produced thereby
BR9807181A (pt) Piridinas 2-amino-substituìdas
MX9803672A (es) Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos.
ATE111081T1 (de) Disubstituierte pyridine.
BG104232A (bg) Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцин- 10-оли, метод за тяхното получаване и приложението им като лекарствени средства
TR200003302T2 (tr) Anti-astım, anti-alerjik, anti-enflamatuar, bağışıklık düzenleyici ve nöro-koruyucu etkiye sahip yeni 1,2,5-trisübstitüe edilmiş 1,2-dihidroindazol-3-onlar, bunların hazırlanması için işlem ve bunların ilaç olarak kullanımı.
HUP9900621A3 (en) 3,4-disubstituted phenylethanolaminotetralincarboxamide derivatives, process to prepare them and pharmaceuticals contg. the said compds.
TR200003596T2 (tr) Hipnotik beta-karbolin türevleri,hazırlanmaları için işlem ve tıbbi ürün olarak kullanımları
ES2159627T3 (es) Formulacion energetica.
MX9804068A (es) Nuevos derivados de quinoxalindiona, su preparacion y empleo en medicamentos.
MX9705084A (es) Piridinas condensadas con heterociclos, procedimiento para su produccion y su uso en medicamentos.